Import Safety Agreement Further Entwines FDA/China Regulatory Process
This article was originally published in PharmAsia News
Executive Summary
Chinese manufacturers of certain drugs or active pharmaceutical ingredients selected by FDA will have to meet new registration standards as part of a memorandum of understanding signed Dec. 11 in Beijing by HHS, FDA and China's State Food and Drug Administration